₹81.94
−0.62%NSE close, 16 Nov 2026
−4.63%
Anuh Pharma is a small cap company, listed on NSE under the symbol ANUHPHR. At ₹81.94 a share, the market values the whole company at ₹821 crore.
In FY26, it reported sales of ₹772 crore and a net profit of ₹41 crore, an operating margin of 8.0%.
The market values the company at 17.2 times its profit over the last twelve months and 2.28 times its book value; its return on equity is 13.3% and its borrowings are 0.05 times its equity.
Promoters hold 71.80% of the shares. Foreign institutions hold 0.11%, and domestic institutions, mutual funds among them, 0.00%.
Over the past year the share price has fallen 4.9%, and it is 17.7% below its 52-week high.
₹ crore. Standalone figures: the company files no consolidated results.
Inauguration of Manufacturing Facility F-10/1 and commencement of commercial production of the Company
Request received for Withdrawal of application for reclassification of shareholding from Promoter & Promoter Group to Public Category
Financial Results
| Sales | 160 | 198 | 186 | 186 | 197 | 202 | 194 | 185 |
|---|---|---|---|---|---|---|---|---|
| Expenses | 145 | 179 | 176 | 174 | 180 | 182 | 178 | 168 |
| Operating profit | 14.8 | 18.7 | 10.3 | 11.9 | 16.8 | 19.9 | 16.3 | 16.9 |
| Operating margin | 9.3% | 9.4% | 5.5% | 6.4% | 8.5% | 9.8% | 8.4% | 9.1% |
| Other income | 0.9 | 1.4 | 3.4 | 1.0 | 4.1 | −1.3 | 3.1 | 0.6 |
| Interest | 0.3 | 0.0 | 0.2 | 0.1 | 0.1 | 0.1 | 0 | 0.1 |
| Depreciation | 2.2 | 2.8 | 2.5 | 2.9 | 3.0 | 3.0 | 2.4 | 2.5 |
| Profit before tax | 13.3 | 17.3 | 11.0 | 9.9 | 17.8 | 15.5 | 16.9 | 15.1 |
| Tax | 2.9 | 4.8 | 2.7 | 2.3 | 4.4 | 3.8 | 5.5 | 3.8 |
| Net profit | 10.3 | 12.5 | 8.3 | 7.6 | 13.5 | 11.7 | 11.4 | 11.2 |
| EPS (₹) | 2.06 | 2.49 | 1.66 | 0.76 | 1.34 | 1.17 | 1.14 | 1.12 |
₹ crore, financial years to March.
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|
| From operations | 37.1 | −3.0 | 26.7 |
| From investing | −19.9 | 17.8 | −29.8 |
| From financing | −4.9 | −26.3 | 4.5 |
| Spent on fixed assets | −20.0 | −7.9 | −1.9 |
| Free cash flow | 17.2 | −10.9 | 24.8 |
Margins, returns, debt, tax and cash.
| Line | FY25 | FY26 |
|---|---|---|
| Net margin | 7.2% | 5.3% |
| Operating margin | 9.2% | 8.0% |
| Return on equity | 14.5% | 11.7% |
| Return on capital employed | 18.3% | 15.5% |
| Return on assets | 9.4% | 7.4% |
| Debt to equity | 0.03 | 0.00 |
| Interest coverage | 99.40 | 116.40 |
| Debt to assets | 0.02 | 0.00 |
| Current ratio | 2.11 | 2.22 |
| Quick ratio | 1.69 | 1.50 |
| Cash ratio | 0.11 | 0.04 |
| Asset turnover | 1.31 | 1.38 |
| Fixed asset turnover | 13.34 | 16.08 |
| Inventory turnover | 6.70 | 4.10 |
| Receivables turnover | 3.10 | 3.20 |
| Gross margin | 24.5% | 22.3% |
| Cash from operations to profit | 78.0% | -7.0% |
| Effective tax rate | 22.4% | 24.3% |
The financial results for the period ended September 30, 2026.
Receiving the possession of manufacturing facility
Signing of Asset Transfer Agreement
Proposal of Investment and availing of Loan
Outcome of Board Meeting held on October 13, 2026 for Investment and availing of Loan.
Orders passed regarding receipt of Demand Order under Section 156 of the Income Tax Act, 1961.
Appointment of Mr Bipin N. Shah, Mr. Arun L. Todarwal and Mr. Ankit Chande as Directors of the company.
General Updates under Regulation 30.